Chronic Lymphocytic Leukemia Clinical Trial

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator’s Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Summary

The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R leukemia-cll/" >CLL or SLL, whose disease has failed treatment with both BTKi and BCL2i targeted therapies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Must have what doctors call measurable disease, which will be evaluated before each participant take part of the study.
Must have received both a BTKi and a BCL2i treatment, and their disease must have come back or not responded to treatment, or they must not have been able to tolerate the side-effects of the BTKi and/or BCL2i treatment(s).
Must also have an ECOG performance score of 0 or 1, which means they are able to carry out their normal daily activities without any problems.

Exclusion Criteria

Heart problems.
Bleeding disorders.
Active cancer in their brain.

Other reasons include:.

i) Having certain treatments in the past.

ii) Having certain infections that are not under control.

iii) Having certain brain conditions.

- Other protocol-defined Inclusion/Exclusion criteria apply.

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 3

Study ID:

NCT06205290

Recruitment Status:

Withdrawn

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 48 Locations for this study

See Locations Near You

Banner MD Anderson Cancer Center
Gilbert Arizona, 85234, United States
Local Institution - 0023
Duarte California, 91010, United States
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento California, 95817, United States
Local Institution - 0120
Atlanta Georgia, 30322, United States
St. Luke's Mountain States Tumor Institute : Boise
Boise Idaho, 83712, United States
Local Institution - 0058
Iowa City Iowa, 52242, United States
Local Institution - 0048
Saint Matthews Kentucky, 40207, United States
Local Institution - 0101
Minneapolis Minnesota, 55455, United States
Local Institution - 0121
New York New York, 10029, United States
Stony Brook University
Stony Brook New York, 11794, United States
Oncology Hematology Care
Cincinnati Ohio, 45242, United States
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States
St. David's South Austin Medical Center
Austin Texas, 78704, United States
Virginia Oncology Associates
Norfolk Virginia, 23502, United States
Local Institution - 0068
Morgantown West Virginia, 26506, United States
University Hospital and UW Health Clinics
Madison Wisconsin, 53792, United States
Local Institution - 0094
Salzburg , 5020, Austria
Local Institution - 0093
Wien , 1090, Austria
Local Institution - 0113
Yvoir Namur, 5530, Belgium
Local Institution - 0112
Leuven Vlaams-Brabant, 3000, Belgium
Local Institution - 0122
Rennes Bretagne, 35033, France
Local Institution - 0036
Montpellier Languedoc-Roussillon, 34295, France
Local Institution - 0038
Lyon Rhône-Alpes, 69008, France
Local Institution - 0035
Clermont-Ferrand , 63100, France
Local Institution - 0037
Paris , 75013, France
Local Institution - 0034
Toulouse , 31100, France
Local Institution - 0084
Dresden Sachsen, 01307, Germany
Local Institution - 0081
Leipzig Sachsen, 04103, Germany
Local Institution - 0083
Kiel Schleswig-Holstein, 24105, Germany
Local Institution - 0079
Heidelberg , D-691, Germany
Local Institution - 0082
Köln , 50937, Germany
Local Institution - 0080
Ulm , 89081, Germany
Local Institution - 0091
Milan Milano, 20162, Italy
Local Institution - 0088
Bologna , 40138, Italy
Local Institution - 0114
Amsterdam Noord-Holland, 1105 , Netherlands
Local Institution - 0117
Groningen , 9713 , Netherlands
Local Institution - 0073
Oslo , 0372, Norway
Local Institution - 0104
Barcelona Barcelona [Barcelona], 08035, Spain
Local Institution - 0105
L'Hospitalet Del Llobregat Barcelona [Barcelona], 08908, Spain
Local Institution - 0107
Santander Cantabria, 39008, Spain
Local Institution - 0108
Madrid Madrid, Comunidad De, 28034, Spain
Local Institution - 0106
Valencia Valenciana, Comunitat, 46010, Spain
Local Institution - 0103
Salamanca , 37007, Spain
Local Institution - 0071
Huddinge , 141 8, Sweden
Local Institution - 0115
London London, City Of, NW1 2, United Kingdom
Local Institution - 0109
London London, City Of, SE5 9, United Kingdom
Local Institution - 0111
Leeds , LS9 7, United Kingdom
Local Institution - 0110
Oxford , 0X3 7, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 3

Study ID:

NCT06205290

Recruitment Status:

Withdrawn

Sponsor:


Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.